Ionis Pharmaceuticals Inc
IONS43.000USD
-0.590-1.35%
Fechamento 07/03, 13:00（ET）Cotações atrasadas em 15 min
6.84BValor de mercado
PerdaP/L TTM
Mais detalhes de Ionis Pharmaceuticals Inc Empresa
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Informações da empresa
Código da empresaIONS
Nome da EmpresaIonis Pharmaceuticals Inc
Data de listagemMay 17, 1991
Fundado em1991
CEODr. Brett P. Monia, Ph.D.
Número de funcionários1069
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 17
Endereço2855 Gazelle Court
CidadeCARLSBAD
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92010
Telefone17609319200
Sitehttps://www.ionis.com/
Código da empresaIONS
Data de listagemMay 17, 1991
Fundado em1991
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
180.98K
-0.30%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
152.00K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
99.49K
-0.03%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
57.02K
+30.71%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
56.66K
+2.15%
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
48.55K
+0.86%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
32.25K
--
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
15.94K
+101.50%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
180.98K
-0.30%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
152.00K
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
-0.03%
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
99.49K
-0.03%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
57.02K
+30.71%
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
56.80K
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 4 de mar
Moeda: USDAtualizado em: ter, 4 de mar
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
Distribuição de ações
Atualizado em: qui, 3 de jul
Atualizado em: qui, 3 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
14.84%
The Vanguard Group, Inc.
10.27%
T. Rowe Price Investment Management, Inc.
10.16%
Capital World Investors
7.77%
Capital Research Global Investors
6.60%
Other
50.36%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
14.84%
The Vanguard Group, Inc.
10.27%
T. Rowe Price Investment Management, Inc.
10.16%
Capital World Investors
7.77%
Capital Research Global Investors
6.60%
Other
50.36%
Tipos de investidores
Investidores
Proporção
Investment Advisor
67.26%
Investment Advisor/Hedge Fund
28.07%
Hedge Fund
13.12%
Research Firm
2.36%
Private Equity
1.60%
Sovereign Wealth Fund
1.08%
Pension Fund
0.93%
Individual Investor
0.81%
Bank and Trust
0.52%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
787
184.68M
116.03%
+8.73M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
2023Q2
770
142.08M
99.29%
+364.04K
2023Q1
825
136.59M
95.51%
-5.80M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
23.61M
14.84%
+924.09K
+4.07%
Mar 31, 2025
The Vanguard Group, Inc.
16.35M
10.27%
-88.61K
-0.54%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
16.18M
10.16%
+323.67K
+2.04%
Mar 31, 2025
Capital World Investors
12.36M
7.77%
+896.58K
+7.82%
Mar 31, 2025
Capital Research Global Investors
10.50M
6.6%
+10.50M
--
May 31, 2025
BlackRock Institutional Trust Company, N.A.
8.90M
5.59%
+21.73K
+0.24%
Mar 31, 2025
Wellington Management Company, LLP
8.42M
5.29%
-255.73K
-2.95%
Mar 31, 2025
Bellevue Asset Management AG
7.85M
4.93%
-15.50K
-0.20%
Mar 31, 2025
State Street Global Advisors (US)
4.85M
3.04%
-581.28K
-10.71%
Mar 31, 2025
Deep Track Capital LP
4.56M
2.87%
+2.63M
+136.01%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qua, 2 de jul
Atualizado em: qua, 2 de jul
Nome
Proporção
ARK Genomic Revolution ETF
3.36%
Tema Neuroscience and Mental Health ETF
2.73%
Capital Group US Small and Mid Cap ETF
2.15%
Virtus LifeSci Biotech Products ETF
1.66%
SPDR S&P Biotech ETF
1.45%
Tema Cardiovascular and Metabolic ETF
1.25%
WisdomTree BioRevolution Fund
1.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.86%
Franklin Genomic Advancements ETF
0.62%
Invesco NASDAQ Future Gen 200 ETF
0.61%
Ver Mais
ARK Genomic Revolution ETF
Proporção3.36%
Tema Neuroscience and Mental Health ETF
Proporção2.73%
Capital Group US Small and Mid Cap ETF
Proporção2.15%
Virtus LifeSci Biotech Products ETF
Proporção1.66%
SPDR S&P Biotech ETF
Proporção1.45%
Tema Cardiovascular and Metabolic ETF
Proporção1.25%
WisdomTree BioRevolution Fund
Proporção1.17%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.86%
Franklin Genomic Advancements ETF
Proporção0.62%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.61%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
